Agilent’s Mass Spectrometer with HPLC Chip Selected by Blue Stream Laboratories Facility
News Apr 30, 2007
Agilent Technologies has announced that Blue Stream Laboratories Inc., a new Boston-based contract product development and testing laboratory, has chosen to equip its protein characterization lab with Agilent’s proteomics tools.
Blue Stream’s management chose Agilent’s products after conducting an in-depth cost-benefit evaluation of instruments offered by Agilent and its chief competitors.
Blue Stream Laboratories specializes in recombinant glycoprotein, peptide and small molecule product characterization, lot release, and stability programs required for pharmaceutical and biopharmaceutical product development. Its services include analytical and in-vitro biological method development, validation and testing; formulation support; and microbiological testing.
At the heart of Blue Stream’s lab setup is Agilent’s HPLC-chip technology, a form of liquid chromatography (LC) separation that replaces the traditional LC nanoflow column and source with a simple, compact microfluidics nanochip. When combined with Agilent’s 6340 ion trap mass spectrometer (MS) equipped with electron transfer dissociation (EDT), it is effective in identifying proteins and post-translational modifications.
Blue Stream’s laboratory also features an Agilent 6210 time-of-flight (TOF) mass spectrometer equipped with both MALDI and electrospray capabilities. In the mix as well are supporting software and a services package.
“These Agilent instruments are helping to establish Blue Stream Laboratories as one of the premier contract research laboratories in the biologics product development and testing space,” explained Blue Stream’s President and Co-Founder Michael Kouchakdjian, Ph.D.
“To our knowledge, Blue Stream is the first commercial lab to use the combination of Agilent’s HPLC chip with its ion trap mass spectrometer with ETD. This unique combination is particularly useful for complex protein characterization studies and will support our growing protein biomarker validation program,” he continued.
“There were many factors that went into our decision,” commented Blue Stream Chief Scientific/Operating Officer Mario DiPaola, Ph.D. “With two distinct but complementary Agilent instruments, we can better service our clients and substantially increase our productivity. Agilent offered us a terrific breadth of portfolio, high reliability and a comprehensive services package.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.